Qiagen N.V. (QGEN)
Chart Events
Performance Outlook
| Previous Close | 49.66 |
| Open | 49.15 |
| Bid | 48.66 x 1000 |
| Ask | 48.66 x 900 |
| Day's Range | 48.36 - 49.09 |
| 52 Week Range | 41.32 - 58.00 |
| Volume | |
| Avg. Volume | 950,980 |
| Market Cap | 11.067B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 19.08 |
| EPS (TTM) | 2.55 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.62 |
- Benzinga
QIAGEN Launches Syndromic Test For QIAstat-Dx For Six Pathogens Similar To Monkeypox
Qiagen NV (NYSE: QGEN) launched the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel – currently for research use only (RUO) – comes in cartridge form to run on Qiagen's QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus (the so-called West African and Congo Basin clades), herpes simplex virus 1 & virus 2, human herpesvirus 6, var
- Business Wire
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
HILDEN, Germany & GERMANTOWN, Md,, August 15, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms.
- Simply Wall St.
Estimating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
How far off is Qiagen N.V. ( NYSE:QGEN ) from its intrinsic value? Using the most recent financial data, we'll take a...
